Orphazyme Teeters On The Brink As Arimoclomol File Is Pulled

NASDAQ Shares Delisted And Workforce Cut By 50%

All hopes for survival rest on a meeting with the US FDA about arimoclomol now that the Danish biotech has withdrawn its submission for the Niemann-Pick disease type C therapy with the European Medicines Agency.

abyss
• Source: Alamy

Orphazyme A/S's annus horribilis is getting more horrible by the week and the latest setback has seen the beleaguered Danish biotech pull the file in Europe for arimoclomol, its investigational treatment for the ultra-rare disorder Niemann-Pick disease type C (NPC).

The company announced on 22 March that it had withdrawn a marketing authorization application to the European Medicines Agency for...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.